Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today … development and further advance our novel Axiomer ® RNAediting platform. With these events we look forward to …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … and ProQR’s RNA oligonucleotide platform and Axiomer RNAediting approaches. Event Details Date/Time: June 22, …
… to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” … Further validate and expand ProQR's proprietary Axiomer ® RNAediting platform through first development candidate …
… opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, Aug. 16, … In May, three abstracts were presented on three of ProQR’s RNAediting approaches for inherited blindness at the Annual …